Member Info for Clenchedcheeks

Steveiom - The following link would appear to show that the trial took place:

https://www.clinicaltrials.gov/ct2/show/study/NCT04358848?term=belluscura&draw=2&rank=2

https://www.clinicaltrials.gov/ct2/show/NCT04299178?term=belluscura&draw=2&rank=1

Steveiom: Strange time to step away if Salarius are on the cusp of something?

Interesting that Companies House records show that Amy Shim is no longer a director of Salarius with effect from 3rd July whereas she still appears on the Salarius website:

Amy is a board advisor and provides guidance on MicroSalt® production and quality standards. She is a client services manager for Tekcapital and helps guide their food-related portfolio. She assists in evaluating the efficacy of MicroSalt® and assessing its future applications on snacks and other foods.

Correction: Sorry - H2 -2019 for Belluscura

In the same way that most of us have capital tied up in TEK shares, I wonder if or how many IP investment opportunities have passed by TEK whilst they attempt to commercialise their investments in Lucyd, Belluscura, Salarius and Guident.

I hope to be proved wrong but if the sales figures in the 2019 accounts for Lucyd are poor and we're then 3/4 of the way through the 2020 financial year, I genuinely believe that they should call time. They've thrown a lot of money at it.

With regards to Belluscura, the constant delays (H1 2019 being the first announcement) cause me some concern. To be so far out on your expected approval date makes you question their capability. Those same delays have cost us dearly in terms of dilution.

BB - The £4m figure is shown in the 2018 accounts of Lucyd Ltd which are available via Companies House. The 2019 figures should be filed by the end of August.

One alarming figure is the Foreign Exchange Transaction loss of 2.7m USD in 2018 particularly bearing in mind they only generated 18,073 USD in Eyewear sales in that year.

Correct me if I'm wrong but in my mind when you run a listed company you do so for the benefit of its shareholders. How can the board of TEK Capital justify such losses in a subsidiary over which they have control?

It's decisions such as this which put doubt in my mind, particularly given the general nature of comments from the board rather than actual numbers such as tonnage of salt sales.

re: TL
I obtained the £4m figure from the November 2018 accounts of Lucyd Ltd.

As of November 2018 they'd spent in excess of £4m generating sales of £18,073.
Sometimes it's better to accept that a product isn't going to catch on, rather than throw more money at it. Instead, Cliff resigned as a director and appointed his son as a director.
Gravy train springs to mind

I agree. You'd think that Belluscura would be familiar with the process bearing in mind they first anticipated approval in 2019.

Also, they must surely have known about the required number of machines and parts when TEK published their annual results in May 2020 and re-emphasised H1 2020.

The November 2019 accounts for both Lucyd and Salarius will be due to be filed at Companies House by 31st August. It's too soon to form an opinion on Salarius but the Lucyd accounts should give an indication as to whether TEK backed and sunk a considerable sum into a lame duck or otherwise.
They need to get one over the line sooner rather than later

Let's just hope that (i) they can secure approval and (ii) it's sooner rather than later in H2. The last thing we want is TEK getting the cap out yet again and seeing further dilution.

re: Ambyth
I contacted the FDA last month as I began to have my doubts on this very question. Unfortunately, they're prohibited from verifying whether a company has a premarket submission currently under review. All they could say was that it had previously been part of a clinical study.
I'm a long term holder here and have no axe to grind, but jumping the gun and quoting anticipated approval dates which can't be delivered does little for confidence.

No big deal!
The share price has been influenced by dates quoted in year end data and a subsequent announcement. Some will no doubt have invested a lot of money on the premise of a very recently quoted anticipated H1 approval. The rising share price reflected that expectation. The result is that some shareholders have overpaid as we're down 27% ten minutes in.

Hugely disappointing, especially given that following a question which I raised, I had an email from them on 22nd May anticipating the process being completed in H1. I doubt the shortages they refer to have occurred since then.
Failure to deliver on anticipated dates not once but more than once doesn't instill great confidence.
One of the original objectives of TEK was to commercialize IP in a shorter time frame than others had previously. To date they've failed.

They (TEK) need to get one over the line.
I've been a holder for years. Whilst I have belief in three of the underlying companies, I'll be hugely disappointed if they don't deliver on the Belluscura H1 announcement.

As a long standing holder, it's like riding a rollercoaster.
Those year end results were superb both in terms of financials and outlook, yet here we are almost two weeks later with a share price that's lower than the net asset value.

Great set of results with an extremely positive outlook.
I'm surprised by the number of sellers and their timing

I apologise for missing the Feb 2020 placing, but the point I was trying to convey was that every nine months or so, Cliff gets his cap out. Sooner or later they need to deliver if they're to retain any credibility.

I don't wish to get into an argument on a message board about Lucyd or Guident. Your opinion differs from mine and I accept that. Securing IP doesn't guarantee returns.

The other two companies offer products with unique features which will hopefully prove to be the golden nuggets. That's why I remain in.

I've a substantial holding and have been invested here for years. My aim is not to talk the price up or down, merely to provide a balanced view. A commercial success is what will increase the share price, not speculative comments on this board. Hopefully we'll agree to disagree and you'll respect the right of others to provide their perspective on how they see it.

re Big Bang 12.22.
If the sales are from one or two sellers, there could be a number of reasons. Cliff has a habit of getting his cap out when good news is in the offing, it's been a while since the previous raise and they've added to their senior staff and overheads in the meantime. The delay regarding FDA approval could be another reason. I'm a long time holder and from memory FDA approval was first expected in H1 2019.
I believe there are others who offer low sodium salt. If it was that unique, someone would have bought them out, they wouldn't have had to produce crisps to try and promote it.
Guident and Lucyd are both long shots in my opinion.
I'm a long term holder and accept that AIM stocks are high risk. What disappoints me most is the absence of any share purchases by Cliff. A director purchase is always a vote of confidence and we've never seen it even when the price was 4p.
I plan to stay with it in the hope that one of their investments will come good in the long term.
Just my thoughts. As usual DYOR and GLA

I appreciate it was early days, but if you look at the sales figures for Lucyd for the year ended 30th November 2018 it was $18,073. Let's see what the November 2019 accounts show but I'm not holding my breath.